fashion -WSS

fashion

author：hotspot 2025-10-01 05:34:03 - browse：69848

Illustration of three connected puzzle pieces, with a woman standing near the missing/empty puzzle piece space. -- first opinion coverage from STAT — Adobe

Women have always been underrepresented in medical research. A new study reveals that not much has changed, especially when it comes to tests of cardiovascular devices.

In a paper published in JAMA Internal Medicine on Monday, researchers found that the percentage of women represented in high-risk medical device trials did not increase from 2010 to 2020. Women generally made up just 33% of participants when the team reviewed 195 trials published from 2016 to 2022. The percentages varied between devices: Women made up 46% of participants in orthopedic trials, but 29% in cardiovascular studies.

The issue isn’t new. The government has made some strides in correcting earlier missteps, like the Food and Drug Administration telling researchers in 1977 to exclude women of reproductive potential from early clinical trials. But stakeholders think agencies like the FDA could do more to incentivize the enrollment of women.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Diverse clinical trials: Why aren’t we there yet?

WSS

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

New Covid vaccine is recommended for everyone 6 months or older

What to make of Biden’s latest efforts on cancer research

Free medical tuition alone isn't enough to close gaps in primary care

How to make the FDA’s new prescription one

Popular nasal decongestant doesn't actually relieve congestion

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Dobbs anniversary: the lost opportunity of abortion as health care

Fertility clinic egg and embryo storage is a disaster

How one medical school became remarkably diverse

STAT reporters are Pulitzer Prize finalists for investigative reporting

Drug repurposing or repositioning? The language matters

FDA proposes changes to key medical devices approval pathway

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

WuXi Biologics execs register to lobby as Congress comes for the company

entertainment

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Telehealth for opioid use disorder is lifesaving

Boston hospital trains restaurant workers on naloxone for overdoses

New weight loss drugs vying to be the next Wegovy or Mounjaro

Private equity could exacerbate cardiology's overuse problem, experts fear

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

entertainment

focus

explore

entertainment